The Avastin vs Visudyne for Neovascular AMD Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00390026|
Recruitment Status : Withdrawn (Lucentis, a treatment superior to PDT, has become available i Sweden.)
First Posted : October 19, 2006
Last Update Posted : May 25, 2007
|Condition or disease||Intervention/treatment||Phase|
|Age-Related Macular Degeneration||Drug: Bevacizumab (Avastin) Drug: Verteporfin photodynamic therapy (PDT)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Prospective, Randomized, Double-Masked, Controlled Study on Intravitreal Bevacizumab (Avastin) Versus Verteporfin (Visudyne) Photodynamic Therapy (PDT) for Patients With Neovascular Age-Related Macular Degeneration (AMD)|
|Study Start Date :||November 2006|
- Proportion of patients losing less than 15 letters on the ETDRS visual acuity chart.
- Proportion of patients gaining more than 15 letters on the ETDRS visual acuity chart.
- Proportion of patients losing more than 30 letters on the ETDRS visual acuity chart.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00390026
|S:t Eriks Eye Hospital|
|Stockholm, Sweden, SE-11282|
|Principal Investigator:||Anders Kvanta, MD, PhD||S:t Erik's Eye Hospital|
|Study Director:||Stefan Seregard, MD, PhD||S:t Eriks Eye Hospital|